



an Open Access Journal by MDPI

Wnt Signaling in Cancer: New Advances

Guest Editor:

Dr. Danilo Predes

Department of Neurology, F. M
Kirby Neurobiology Center,
Boston Children's Hospital,
Boston, MA, USA

Deadline for manuscript
submissions:

20 December 2024

Message from the Guest Editor

Dear Colleagues,

Wnt signaling is one of the most fundamental signaling pathways in Metazoa. Depending on different combinations of ligands and receptors, the Wnt signaling transduction cascade can activate different pathways, which are categorized into two main groups: the canonical (or β -catenin-dependent) Wnt/ β -catenin signaling pathway and the non-canonical (or β -catenin-independent) pathways. These pathways regulate key aspects of embryonic development by controlling differentiation, proliferation, and migration. Numerous malignant tumors have been described as modulated by Wnt signaling, such as Colorectal cancer, Breast cancer, Skin cancer, Pancreatic cancer, Liver cancer, and Leukemia, among others. However, to date, there are no FDA-approved specific Wnt-targeting therapies.

In this Special Issue, we will focus on novel findings in the regulation of neoplasia through Wnt signaling, reviews detailing the relevance of this pathway to tumorigenesis, and the potential of targeting Wnt signaling as a therapeutic strategy to treat cancer.

I look forward to your contribution.

Dr. Danilo Predes
Guest Editor



mdpi.com/si/205634

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com